SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is seeing a significant intraday rebound, fueled by former President Trump's comments hinting that the Iran conflict "could be over soon," which has triggered a sharp reversal in oil prices and spurred community debate about market manipulation and a massive short squeeze.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is seeing a dramatic intraday reversal, surging from early lows following remarks suggesting a rapid de-escalation of the Iran conflict and a corresponding drop in oil prices. While bulls celebrate the resilience and a "V reversal," many in the community are questioning if this is a manipulated short-squeeze, with broad skepticism about the market's defiance of ongoing geopolitical and economic concerns.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is trending with extreme volatility as escalating Middle East tensions and threats to global oil supply from the Strait of Hormuz have driven a sharp price surge. However, community sentiment is now divided between those anticipating sustained higher prices and those expecting a rapid pullback following G7 discussions and actions concerning the release of strategic oil reserves.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply higher after reaching a transformative deal with Novo Nordisk to distribute its branded weight-loss drugs, effectively resolving a patent lawsuit and eliminating a major regulatory overhang. This news is igniting widespread community speculation about a significant short squeeze, with many anticipating a continued upward trajectory for the digital health platform.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as its partners were selected for a pivotal White House eVTOL Integration Pilot Program, driving community discussion around this major step toward air taxi commercialization and its recent achievement of 100% FAA Means of Compliance for its Midnight aircraft.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is a major talking point as geopolitical tensions are pushing oil prices higher, leading to community debate over a potential surge in EV demand. This comes as the market awaits a crucial NHTSA report on Robotaxi safety, while also digesting news of high-profile executive departures, contributing to polarized investor sentiment.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending as its community buzzes about the unique real-world asset (RWA) integration via Cocky Wings LLC, fueling token buybacks and passive income opportunities through its Cardano-based staking arena.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is gaining attention following NOAA's determination that its deep-sea mining application is in "substantial compliance," a pivotal regulatory step that the community largely interprets as de-risking the project and accelerating pathways to commercial permits. This comes as global geopolitical factors underscore an urgent need for independent critical mineral supply chains, driving conviction among investors about TMC's long-term potential.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending amid escalating Middle East tensions and surging oil prices, sparking intense community debate on potential market volatility and a broader correction, as traders utilize this leveraged ETF to hedge or speculate on rising fear.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is a battleground stock as the community debates whether concerns over rising fuel costs from the Iran war, potentially delaying airline orders, outweigh the impact of a massive rumored aircraft deal from China and anticipated increases in defense spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are currently covering the firm...

Oppenheimer Has Lowered Expectations for Aardvark Therapeutics (NASDAQ:AARD) Stock Price

Oppenheimer cut their price target on Aardvark Therapeutics from $35.00 to $21.00 and set an "outperform" rating for the company in a report on Monday...

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

Equity

Aardvark Therapeutics (NASDAQ:AARD) Given New $9.00 Price Target at BTIG Research

BTIG Research reduced their price objective on shares of Aardvark Therapeutics from $26.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...

Aardvark Therapeutics (NASDAQ:AARD) Earns "Equal Weight" Rating from Morgan Stanley

Morgan Stanley restated an "equal weight" rating and issued a $7.00 target price (down from $29.00) on shares of Aardvark Therapeutics in a research report on Monday...

HC Wainwright Reaffirms Neutral Rating for Aardvark Therapeutics (NASDAQ:AARD)

HC Wainwright restated a "neutral" rating on shares of Aardvark Therapeutics in a research report on Monday...

Aardvark Therapeutics' (AARD) "Hold" Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reaffirmed a "hold" rating and set a $6.00 price target (down from $24.00) on shares of Aardvark Therapeutics in a research note on Monday...

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ...

<ul class="summary-bullets"><li>Aardvark was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial.</li><li>In September, Acadia Pharmaceuticals scrapped development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.</li><li>Soleno Therapeutics’ VYKAT XR is the first approved treatment specifically for hyperphagia in PWS patients.</li></ul>Shares of Aardvark Therapeutics (AARD) dived 53% after hours on Friday after the company announced that it is voluntarily pausing its late-stage trial in Prader-Willi Syndrome (PWS).The company was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial. Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.<h2 class="st-heading-2">Why Is Aardvark Pausing Trial?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aardvarktherapeutics.com/news-releases/news-release-details/aardvark-therapeutics-announces-voluntary-pause-phase-3-hero">said</a> that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. The company is reviewing the data to determine next steps, it said, while adding that it has also paused enrollment and dosing in the trial as it completes its evaluation.The firm also added that it no longer expects data from the trail in the third quarter of 2026.<h2 class="st-heading-2">Other Names To Quit PWS Drug Development</h2>In September, Acadia Pharmaceuticals <a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">scrapped</a> development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.The company then said that intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials and also announced its intent to stop investigating the drug further.<h2 class="st-heading-2">Soleno’s Approved Drug</h2>Soleno Therapeutics, meanwhile, received FDA approval of VYKAT XR in early 2025, making it the first approved treatment specifically for hyperphagia in PWS patients.However, in August, Scorpion Capital revealed a short position against Soleno stock, alleging several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. Scorpion Capital also stated that it intends to submit an emergency Citizen Petition shortly, requesting that the FDA urge Soleno to conduct a voluntary recall of Vykat XR from the market.Weeks later, in September, the company <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-stock-tanks-after-patient-treated-with-drug-dies/chwklo0RdHG">stated</a> in a filing with the Securities and Exchange Commission that it is aware of a serious adverse event reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) involving a deceased patient. However, the existence of a report in the data does not establish causation, the company said.Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AARD rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/AARD">AARD stock</a> has dropped 7% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sls-stokes-retail-anticipation-for-breakout-rally/cZTcDCwRITx">SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts 

The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.

Aardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline

(RTTNews) - Aardvark Therapeutics Inc. (AARD) announced on Thursday the formation of Ardia Therapeutics Inc., a wholly owned U.S. subsidiary focused on building a dermatology pipeline...

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

AARD
Aardvark Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AARD News

AARDAardvark Therapeutics Inc